Fount of Information

AcroBiosystems社 DLL3: an emerging target in small cell lung cancer

この製品に関するご意見・ご照会・お問合せはこちら

Acro_logo.png

Products

Support

Scientific Talk

 COVID-19 R&D

About Us

 

DLL3: an emerging target in small cell lung cancer

 


 Small cell lung cancer (SCLC) is a subtype of lung cancer, which accounts for about 15% of all lung cancer cases. Delta-like 3 (DLL3) is an attractive target for SCLC immunotherapy since its expression is highly restricted to SCLC with a neglectable appearance on normal adult tissues.

 

Table 1. DLL3 Clinical Drug Information>
Table1.png

DSL_Domain.jpg

ACROBiosystems has developed an exclusive collection of DLL3 proteins to support the development of DLL3-targeted therapy.

  

FITC\Biotin labeled DLL3 proteins.

 

Ideal for anti- DLL3 CAR expression and antibody screening.

 

More species and tags to choose from.


 

Hot Product List

Hot_product_list.png

 


 

DL3-HF2H4.jpg

DL3-H52H4.jpg
                    DLH3-HF2H4Potocol.PNG                     DL3-H52H4
Potocol.PNG

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。